Rheumatology Grand Rounds 2025 Rheumatology Grand Rounds 2025 - Lupus Nephritis

February 21, 2025 – 9:00 AM

Tucson

Overall Activity Objectives:

1 Use practice algorithms designed specifically for rheumatic practice.

2 Utilize tests, imaging, procedures and interventions (i.e., non-pharmacologic, pharmacologic and surgical) with greater accuracy and more cost-effectively.

3 Diagnose patients with rheumatic and musculoskeletal diseases with greater accuracy.

4 Utilize appropriate clinical instruments to assess disease activity and functional outcomes.

5 Manage patients with rheumatic and musculoskeletal diseases with improved accuracy. 6 Avoid and/or minimize adverse events.

7 Improve patient outcomes for patients with rheumatic and musculoskeletal diseases.

Session Objectives:

1 Recognize Lupus nephritis as an unmet need in the care of patient with systemic lupus 2 Understand the key changes for the 2024 American College of Rheumatology Lupus nephritis guidelines

3 Learn about recent advances in the treatment of Lupus nephritis

Accreditation Statement:

The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Arizona College of Medicine - Tucson designates this Live Activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Relevant Financial Relationships Statement(s):

University of Arizona College of Medicine - Tucson Office of Continuing Medical Educationadheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Ernest R Vina, MD	Activity Director	Nothing to disclose - 11/05/2024
Fotios Koumpouras, MD	Faculty	Advisor-Miltenyi Biotec (Relationship has ended) Advisor-Atara Bio (Relationship has ended) Grant or research support-Gilead Sciences, Inc. Grant or research support-AbbVie (Any division) Grant or research support-Bristol-Myers Squibb Company Consulting Fee-Cabaletta Bio (Relationship has ended) Advisor-

Adicet Bio (Relationship has ended) Grant or research support- Lupus Research Alliance Grant or research support-Novartis Corporation Pharmaceuticals Grant or research support-Gilead Sciences, Inc
02/13/2025

